<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04870606</url>
  </required_header>
  <id_info>
    <org_study_id>GT0918-US-3001</org_study_id>
    <nct_id>NCT04870606</nct_id>
  </id_info>
  <brief_title>Proxalutamide (GT0918) Treatment for Outpatients With Mild or Moderate COVID-19 Illness</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Proxalutamide (GT0918) in Outpatients With Mild to Moderate COVID-19 Illness</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suzhou Kintor Pharmaceutical Inc,</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Suzhou Kintor Pharmaceutical Inc,</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and safety of Proxalutamide (GT0918) as a&#xD;
      treatment for outpatients COVID-19 subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 5, 2021</start_date>
  <completion_date type="Anticipated">May 24, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 24, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of Proxalutamide</measure>
    <time_frame>28 days</time_frame>
    <description>percentage of hospitalization</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">668</enrollment>
  <condition>Efficacy and Safety</condition>
  <arm_group>
    <arm_group_label>GT0918+ standard of care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo+ standard of care</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Proxalutamide (GT0918)</intervention_name>
    <description>Proxalutamide (GT0918)+Standard of care determined by PI and local regulatory</description>
    <arm_group_label>GT0918+ standard of care</arm_group_label>
    <other_name>standard of care</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo+Standard of care determined by PI and local regulatory</description>
    <arm_group_label>placebo+ standard of care</arm_group_label>
    <other_name>standard of care</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The subject or legally authorized representative give signed informed consent which&#xD;
             includes compliance with the requirements and restrictions listed in the ICF and in&#xD;
             this protocol.&#xD;
&#xD;
          2. Understand and agree to comply with planned study procedures.&#xD;
&#xD;
          3. Male subjects with age ≥18 years of age at the time of randomization.&#xD;
&#xD;
          4. Are currently not hospitalized.&#xD;
&#xD;
          5. Have one or more mild or moderate symptom(s) COVID-19-related symptoms within 5 days&#xD;
             of onset of symptoms onset&#xD;
&#xD;
          6. Must have first positive SARS-CoV-2 viral infection determination (has&#xD;
             laboratory-confirmed SARS-CoV-2 infection as determined by PCR, or other commercial or&#xD;
             public health assay in any specimen) ≤3 days prior to start of the first dose.&#xD;
&#xD;
          7. Regardless of their fertility status, male subjects must agree to either remain&#xD;
             abstinent (if this is their preferred and usual lifestyle) or use condoms as well as&#xD;
             one additional highly effective method of contraception (less than 1% failure rate) or&#xD;
             effective method of contraception with nonpregnant women of childbearing potential&#xD;
             partners for the duration of the study and until 90 days after the last dose.&#xD;
&#xD;
             Use an acceptable method of contraception such as:&#xD;
&#xD;
               -  Highly effective methods of contraception (less than 1% failure rate) comprise,&#xD;
                  but are not limited to&#xD;
&#xD;
                    -  combination oral contraceptives&#xD;
&#xD;
                    -  implanted contraceptives, or&#xD;
&#xD;
                    -  intrauterine devices.&#xD;
&#xD;
               -  Effective methods of contraception comprise but are not limited to&#xD;
&#xD;
                    -  diaphragms with spermicide or cervical sponges.&#xD;
&#xD;
                    -  men and their partners may choose to use a double-barrier method of&#xD;
                       contraception that must include use of a spermicide.&#xD;
&#xD;
          8. Agree to the collection of nasopharyngeal swabs and venous blood.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have SpO2 ≤ 93% on room air at sea level or PaO2/FiO2 &lt; 300, respiratory rate ≥30 per&#xD;
             minute, heart rate ≥125 per minute&#xD;
&#xD;
          2. Estimated glomerular filtration rate (eGFR) &lt; 30 ml/min&#xD;
&#xD;
          3. Serum total bilirubin &gt; 1.5 x ULN (upper limit of normal) and AST and ALT &gt;3x ULN&#xD;
&#xD;
          4. Subjects with significant cardiovascular disease as following:&#xD;
&#xD;
             i. heart failure NYHA class ≥3 ii. left ventricular ejection fraction &lt;50% iii. those&#xD;
             with a history of cardiac arrhythmias, including long QT syndrome.&#xD;
&#xD;
          5. Has been admitted to a hospital prior to randomization, or is hospitalized (inpatient)&#xD;
             at randomization, due to COVID-19 or requires treatment with supplemental oxygen.&#xD;
&#xD;
          6. Have known allergies to any of the components used in the formulation of the&#xD;
             interventions.&#xD;
&#xD;
          7. Have hemodynamic instability requiring use of vasopressors within 24 hours of&#xD;
             randomization.&#xD;
&#xD;
          8. Suspected or proven serious, active bacterial, fungal, viral, or other infection&#xD;
             (except COVID-19) that in the opinion of the investigator could constitute a risk when&#xD;
             taking intervention (i.e. known history of human immunodeficiency virus [HIV]).&#xD;
&#xD;
          9. Have any co-morbidity requiring surgery within &lt;7 days, or that is considered&#xD;
             life-threatening within 30 days.&#xD;
&#xD;
         10. Have any serious concomitant systemic disease, condition, or disorder that, in the&#xD;
             opinion of the investigator, should preclude participation in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Clinical operation</last_name>
    <phone>86-512-62639909</phone>
    <email>kintor.co@kintor.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Absolute Clinical Research</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85051</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Long Beach Clinical Trials</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>WR-Mount Vernon Clinical Research, LLC</name>
      <address>
        <city>Sandy Springs</city>
        <state>Georgia</state>
        <zip>29677</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Olivo Medical and Wellness Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60618</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gtc Research</name>
      <address>
        <city>Shawnee Mission</city>
        <state>Kansas</state>
        <zip>66218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Platinum Research Network, LLC</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Main Street Physician's Care</name>
      <address>
        <city>Little River</city>
        <state>South Carolina</state>
        <zip>29566</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lotus Clinical Research</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 27, 2021</study_first_submitted>
  <study_first_submitted_qc>April 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2021</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

